Clinical & Translational Research > Pancreatic Cancer > Dr Eithne Costello-Goldring

	Every year in the UK, around 7,000 people are diagnosed with pancreatic cancer. Unfortunately, the disease is often diagnosed at a late stage and is difficult to treat effectively. Although surgery to remove the cancer followed by chemotherapy, offers a significant survival advantage, only a small proportion of patients undergo potentially curative surgery and most patients die from the disease within 6-8 months of diagnosis. Markers to facilitate earlier diagnosis (enabling surgery) are needed, as are markers that provide prognostic or predictive information regarding the likelihood of a person to respond to treatment. Here at Liverpool we undertake analysis of pancreatic cancer cells, tissue and blood from patients with pancreatic cancer and disease controls. We wish to understand the biology of the disease and to find markers that will enable the early detection of pancreatic cancer.
Contact Details Tel: 0151 706 4178 Email: Ecostell@liverpool.ac.uk

Eithne gained a B.Sc. and PhD in Pharmacology, at University College Dublin, Ireland. She spend seven years in Switzerland, one at the University of Berne whilst doing her PhD, and six further years in Lausanne as a postdoctoral fellow, firstly at ISREC, the Swiss Institute for Cancer Research, and subsequently at the Institute of Microbiology, University of Lausanne.

In 1999 she took up post in the Division of Surgery and Oncology at the University of Liverpool, where she established a research group within the larger pancreatic research group focussed on the application of proteomic-based technology to pancreatic cancer, and more recently colorectal cancer. The current focus is on proteomic analysis of serum and pancreatic juice samples, using techniques such as iTRAQ. Proteins identified as abnormally expressed in cancer are subjected to further molecular characterisation and/or evaluated for their potential as disease biomarkers using a variety of techniques including mass spectrometry.

Her involvement with the Liverpool Experimental Cancer Medicine Centre re-enforces the translational aspect of her work. She co-directs the GCLP laboratories.

Her research is currently funded by Cancer Research UK and the Pancreatic Cancer Research Fund (http://www.pcrf.org.uk/).

Education and qualifications

1993: PhD, University College Dublin, Ireland.

1988: BSc (Hons) 2.1, University College Dublin, Ireland.

Appointments

2009: Reader, Division of Surgery and Oncology, University of Liverpool.

2005: Senior Lecturer, Division of Surgery and Oncology, University of Liverpool.

1999: Lecturer, Division of Surgery and Oncology, University of Liverpool.

1996: Postdoctoral Fellow, University of Lausanne, Switzerland.

1993: Postdoctoral Fellow, ISREC - Swiss Institute for Cancer Research.

Memberships of Societies and Committees

European Pancreatic Club, (2000-date: Council Member 2007 to 2011)

British Society for Proteome Research (2005-date)

British Association for Cancer Research (2002-date)

International Association of Pancreatology (2000-date: Member of Scientific Committee, from 2007 to 2010)

National Cancer Research Institute (NCRI) Translational/ Correlative Science Clinical Studies Group, October 2009-date

Pancreatic Society of Britain and Ireland (2000-date).

Shekouh AR, Thompson CC, Prime W, Campbell F, Hamlett J,  Herrington CS, Lemoine NR, Tatjana Crnogorac-Jurcevic, Buechler MW, Friess H, Neoptolemos JP,  Pennington SR, and Costello E. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics(2003), 3, 1988–2001.

Tweedle E, Khattak I, Ang C, Nedjadi T, Jenkins R, Park BK, Kalirai H, Dodson A, Azadeh B, Terlizzo M, Grabsch H, Myint S, Clark P, Wong H, Greenhalf W, Neoptolemos JP, Rooney PS, Costello E. Low Molecular Weight Heat Shock Protein, HSP27 is a prognostic indicator in rectal cancer, but not colon cancer. (2010) Accepted for publication in GUT

Ang CW, Nedjadi T, Sheikh A, Tweedle E, Tonack S, Honap S, Jenkins R, Park BK, Schwarte-Waldhoff I, Khattak I, Azadeh B,Dodson A, Kalirai H, Neoptolemos JP, Rooney PS, and Costello E. Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Accepted for Publication in Carcinogenesis.

Tweedle E, Khattak I, Ang C, Nedjadi T, Jenkins R, Park BK, Kalirai H, Dodson A, Azadeh B, Terlizzo M, Grabsch H, Myint S, Clark P, Wong H, Greenhalf W, Neoptolemos JP, Rooney PS, Costello E. Low Molecular Weight Heat Shock Protein, HSP27 is a prognostic indicator in rectal cancer, but not colon cancer. (2010) Accepted for publication in GUT

Christoph Schröder, Anette Jacob, Sarah Tonack, Tomasz P. Radon, Martin Sill, Manuela Zucknick, Sven Rüffer, Eithne Costello, John P. Neoptolemos, Tatjana Crnogorac-Jurcevic, Andrea Bauer, Kurt Fellenberg, and Jörg D. Hoheisel. Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Molecular and Cellular Proteomics. 2010 Epub Feb 16.

Tonack S, Aspinall-O Dea M, Jenkins RE, Elliot V, Murray S, Lane CS, Kitteringham NR, Neoptolemos JP, Costello E. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics. 2009 Dec 1;73(2):352-6. Epub 2009 Aug 3.

Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, Ashcroft F, Tepikin A, Neoptolemos JP, Costello E. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer. 2009 Oct 6;101(7):1145-54. Epub 2009 Sep 1.2009 Sep 1.

Yan L; Tonack S, Smith R;, Dodd S; Jenkins, R, Kitteringham N; Greenhalf W; Ghaneh P; Costello E. The confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Research 2009;8(1):142-8.

Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E. Pancreatic Cancer Cells overexpress Gelsolin Family Capping Proteins, which contribute to their cell motility. GUT 2007;56(1):95-106.

Sheikh A, Vimalachandran D, Thompson C, Jenkins R, Nedjadi T, Shekouh A, Campbell F, Dodson A, Prime W, Crnogorac-Jurcevic T, Lemoine N, Costello E. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics2007; 7(11):1929-1940.

G Saraga, A Mafficini, P Ghaneh, C Sorio and E Costello. Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. Cancer Gene Therapy, 2007;14(9):781-90.

Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello E, Neoptolemos J, Lemoine NR. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology, 2005; 129(5):1454-63.

Vimalachandran D, Greenhalf W, Thompson C, Luttges J, Prime W, Campbell F, Dodson A, Watson R, Crnogorac-Jurcevic T, Lemoine N, Neoptolemos J, Costello E. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res. 2005; 65(8):3218-25.

Missiaglia E, Blaveri E, Terris B, Wang YH, Costello E, Neoptolemos JP, Crnogorac-Jurcevic T, Lemoine NR. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis International Journal of Cancer 2004, 112(1):100-12.

Halloran CM., Ghaneh P., Shore S., Greenhalf W., Zumstein L., Wilson D., Neoptolemos J.P. and Costello E. 5-flurouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med. 2004 (5):514-25.

Shekouh AR, Thompson CC, Prime W, Campbell F, Hamlett J,  Herrington CS, Lemoine NR, Tatjana Crnogorac-Jurcevic, Buechler MW, Friess H, Neoptolemos JP,  Pennington SR, and Costello E. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics(2003), 3, 1988–2001.

Crnogorac-Jurcevic T., Missiaglia E., Blaveri E., Gangeswaran R., Jones M., Terris B., Costello E., Neoptolemos J. P., and Lemoine N. R. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. (2003) J Pathol. (2003) 201(1):63-74

Invited Review Articles; all peer-reviewed

E Shaw, DJ Naisbitt, E Costello, W Greenhalf, BK Park, JP Neoptolemos and GW Middleton. The Current Status of GV1001 and Other Telomerase Vaccination Strategies in the Treatment of Cancer. Expert Review of Vaccines June 2010 Accepted.

Sarah Tonack, Mark Aspinall-O’Dea, John P. Neoptolemos and Eithne Costello*. Pancreatic cancer: Proteomic approaches to a challenging disease Pancreatology 2009 Aug 4;9(5):567-576. [Epub ahead of print]

Middleton G, Ghaneh P, Costello E, Greenhalf W, Neoptolemos JP. New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2008;2(5):673-96.

Ghaneh P, Costello E, and Neoptolemos JP. Biology and Management of Pancreatic Cancer 2007 GUT2007;6(8):1134-52.

Aspinall-O’Dea M and Costello E. The Pancreatic Cancer Proteome – Recent Advances and Future Promise Proteomics-Clinical Applications 2007;1(9)1066-79.

Halloran CM, Ghaneh P, Costello E, Neoptolemos JP. Trials of gene therapy for pancreatic carcinoma. Curr Gastroenterol Rep. 2005;7:165-9

Vimalachandran, D. and Costello, E, Proteomic technologies and their application to pancreatic cancer. Expert Rev. Proteomics 1 (4), 2004, 493-501.

Genetics and Prevention of Pancreatic Cancer Vimalachandran D., Ghaneh P., Costello E. and. Neoptolemos J. P. Cancer Control (2004), Vol. 11, No. 1.

Aspinall-O’Dea. M, Neoptolemos. JP, Costello. E Proteomic analysis of blood and pancreatic juice (2010) Drug Discovery in Pancreatic Cancer: Models and Techniques (Ed Grippo. P and Han. H)

Sarah Tonack, John Neoptolemos, Eithne Costello Principles and applications of proteomics in pancreatic cancer. (2009) Handbook of Pancreatic Cancer, John Neoptolemos, Markus Büchler, James Abbruzzese, Raul Urrutia (Eds.) Springer.

Costello E. Molecular biological understanding of development of pancreatic cancer. In The Pancreas: A Clinical and Surgical Text, 2e (2008) Eds Hans Beger, Markus Büchler, Richard Kozarek, Markus Lerch, John Neoptolemos, Keiko Shiratori, Andrew Warshaw and David Whitcomb. Chapter 58, p583-590.

Shore, S, Vimalachandran D, Neoptolemos J.P. and Costello E. Proteomic analysis of pancreas samples using two-dimensional electrophoresis combined with mass spectrometry. In Exocrine Pancreas Cancer, (2005) Eds Gress,T., Neoptolemos, JP., Lemoine, NR. Real., FX. Also available at:

P. Ghaneh, C.M. Halloran, E. Costello and J.P. Neoptolemos. Novel alternatives to chemotherapy in advanced disease- gene transfer. (2004) Pancreatic Disease Eds Johnson CD Imrie, CW.